settings, because in the "real world" those lung cells express the protease TMPRSS2 which inhibits the effectiveness of HCQ...that's why no one apparently wants to invest in it...at least that's my admittedly personal opinion after reading this paper...(see link)
Another perspective...There are other papers I came across (see link after this paragraph) that discuss in deep esoteric detail the complexity of finding a drug that will specifically inhibit the spike protein found on the SARS-COV-2...and they include what seems to be hundreds of candidates...what are the odds of a simple off-the-shelf anti-malaria drug being the "perfect solution" to this highly complex problem?...seriously...what are the odds?
https://www.frontiersin.org/articles/10.3389/fchem.2021.622898/full
Here is an excerpt from the linked report that describes the studies of HCQ snd the TMPRSS2 protease....
"Author summary
The novel pathogenic coronavirus SARS-CoV-2 causes COVID-19 and remains a threat to global public health. Chloroquine and hydroxychloroquine have been shown to prevent viral infection in cell-culture systems, but human clinical trials did not observe a significant improvement in COVID-19 patients treated with these compounds. Here we show that hydroxychloroquine interferes with only one of two somewhat redundant pathways by which the SARS-CoV-2 spike (S) protein is activated to mediate infection. The first pathway is dependent on the endosomal protease cathepsin L and sensitive to hydroxychloroquine, whereas the second pathway is dependent on TMPRSS2, which is unaffected by this compound. We further show that SARS-CoV-2 is more reliant than SARS coronavirus (SARS-CoV-1) on the TMPRSS2 pathway, and that this difference is due to a furin cleavage site present in the SARS-CoV-2 S protein. Finally, we show that combinations of hydroxychloroquine and a clinically tested TMPRSS2 inhibitor work together to effectively inhibit SARS-CoV-2 entry. Thus TMPRSS2 expression on PHYSIOLOGICALLY RELEVANT SARS-CoV-2 TARGET CELLS (e.g. Lung Tissue) may bypass the antiviral activities of hydroxychloroquine, and explain its lack of in vivo efficacy."
It's been educating for me to go through some of this material...kind of fun, actually, but there are limits, and I can see the end on this one...you're welcome to carry on, but please don't spend your hard earned money on HCQ and for heaven's sake, please don't get involved in trying to sell it.
Link: https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009212